Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

CD49a Expression Identifies a Subset of Intrahepatic Macrophages in Humans.

Martrus G, Goebels H, Langeneckert AE, Kah J, Flomm F, Ziegler AE, Niehrs A, Löbl SM, Russu K, Hess LU, Salzberger W, Poch T, Nashan B, Schramm C, Oldhafer KJ, Dandri M, Koch M, Lunemann S, Altfeld M.

Front Immunol. 2019 Jun 7;10:1247. doi: 10.3389/fimmu.2019.01247. eCollection 2019.

2.

Down-regulation of cell membrane localized NTCP expression in proliferating hepatocytes prevents hepatitis B virus infection.

Yan Y, Allweiss L, Yang D, Kang J, Wang J, Qian X, Zhang T, Liu H, Wang L, Liu S, Sui J, Chen X, Dandri M, Zhao J, Lu F.

Emerg Microbes Infect. 2019;8(1):879-894. doi: 10.1080/22221751.2019.1625728.

3.

T cell receptor grafting allows virological control of Hepatitis B virus infection.

Wisskirchen K, Kah J, Malo A, Asen T, Volz T, Allweiss L, Wettengel JM, Lütgehetmann M, Urban S, Bauer T, Dandri M, Protzer U.

J Clin Invest. 2019 Apr 30;129(7):2932-2945. doi: 10.1172/JCI120228.

4.

A global scientific strategy to cure hepatitis B.

Revill PA, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F.

Lancet Gastroenterol Hepatol. 2019 Jul;4(7):545-558. doi: 10.1016/S2468-1253(19)30119-0. Epub 2019 Apr 10. Erratum in: Lancet Gastroenterol Hepatol. 2019 Jul;4(7):e7.

5.

Comparative analysis of the antiviral effects mediated by type I and III interferons in hepatitis B virus infected hepatocytes.

Bockmann JH, Stadler D, Xia Y, Ko C, Wettengel JM, Zur Wiesch JS, Dandri M, Protzer U.

J Infect Dis. 2019 Mar 29. pii: jiz143. doi: 10.1093/infdis/jiz143. [Epub ahead of print]

PMID:
30923817
6.

Interactions Between KIR3DS1 and HLA-F Activate Natural Killer Cells to Control HCV Replication in Cell Culture.

Lunemann S, Schöbel A, Kah J, Fittje P, Hölzemer A, Langeneckert AE, Hess LU, Poch T, Martrus G, Garcia-Beltran WF, Körner C, Ziegler AE, Richert L, Oldhafer KJ, Schulze Zur Wiesch J, Schramm C, Dandri M, Herker E, Altfeld M.

Gastroenterology. 2018 Nov;155(5):1366-1371.e3. doi: 10.1053/j.gastro.2018.07.019. Epub 2018 Jul 19.

PMID:
30031767
7.

Nonlytic Lymphocytes Engineered to Express Virus-Specific T-Cell Receptors Limit HBV Infection by Activating APOBEC3.

Koh S, Kah J, Tham CYL, Yang N, Ceccarello E, Chia A, Chen M, Khakpoor A, Pavesi A, Tan AT, Dandri M, Bertoletti A.

Gastroenterology. 2018 Jul;155(1):180-193.e6. doi: 10.1053/j.gastro.2018.03.027. Epub 2018 Mar 14.

PMID:
29550589
8.

Multi-color RGB marking enables clonality assessment of liver tumors in a murine xenograft model.

Thomaschewski M, Riecken K, Unrau L, Volz T, Cornils K, Ittrich H, Heim D, Wege H, Akgün E, Lütgehetmann M, Dieckhoff J, Köpke M, Dandri M, Benten D, Fehse B.

Oncotarget. 2017 Dec 14;8(70):115582-115595. doi: 10.18632/oncotarget.23312. eCollection 2017 Dec 29.

9.

Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo.

Giersch K, Bhadra OD, Volz T, Allweiss L, Riecken K, Fehse B, Lohse AW, Petersen J, Sureau C, Urban S, Dandri M, Lütgehetmann M.

Gut. 2019 Jan;68(1):150-157. doi: 10.1136/gutjnl-2017-314713. Epub 2017 Dec 7.

PMID:
29217749
10.

Efficacy of NVR 3-778, Alone and In Combination With Pegylated Interferon, vs Entecavir In uPA/SCID Mice With Humanized Livers and HBV Infection.

Klumpp K, Shimada T, Allweiss L, Volz T, Lütgehetmann M, Hartman G, Flores OA, Lam AM, Dandri M.

Gastroenterology. 2018 Feb;154(3):652-662.e8. doi: 10.1053/j.gastro.2017.10.017. Epub 2017 Oct 24.

PMID:
29079518
11.

A novel orally available small molecule that inhibits hepatitis B virus expression.

Mueller H, Wildum S, Luangsay S, Walther J, Lopez A, Tropberger P, Ottaviani G, Lu W, Parrott NJ, Zhang JD, Schmucki R, Racek T, Hoflack JC, Kueng E, Point F, Zhou X, Steiner G, Lütgehetmann M, Rapp G, Volz T, Dandri M, Yang S, Young JAT, Javanbakht H.

J Hepatol. 2018 Mar;68(3):412-420. doi: 10.1016/j.jhep.2017.10.014. Epub 2017 Oct 25.

PMID:
29079285
12.

Animal models of HBV infection.

Dandri M, Petersen J.

Best Pract Res Clin Gastroenterol. 2017 Jun;31(3):273-279. doi: 10.1016/j.bpg.2017.04.014. Epub 2017 May 5. Review.

PMID:
28774409
13.

Lymphocytes transiently expressing virus-specific T cell receptors reduce hepatitis B virus infection.

Kah J, Koh S, Volz T, Ceccarello E, Allweiss L, Lütgehetmann M, Bertoletti A, Dandri M.

J Clin Invest. 2017 Aug 1;127(8):3177-3188. doi: 10.1172/JCI93024. Epub 2017 Jul 24.

14.

The Role of cccDNA in HBV Maintenance.

Allweiss L, Dandri M.

Viruses. 2017 Jun 21;9(6). pii: E156. doi: 10.3390/v9060156. Review.

15.

Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice.

Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, Petersen J, Buti M, Pollicino T, Sureau C, Dandri M, Lütgehetmann M.

Sci Rep. 2017 Jun 16;7(1):3757. doi: 10.1038/s41598-017-03946-9.

16.

Cold-induced conversion of cholesterol to bile acids in mice shapes the gut microbiome and promotes adaptive thermogenesis.

Worthmann A, John C, Rühlemann MC, Baguhl M, Heinsen FA, Schaltenberg N, Heine M, Schlein C, Evangelakos I, Mineo C, Fischer M, Dandri M, Kremoser C, Scheja L, Franke A, Shaul PW, Heeren J.

Nat Med. 2017 Jul;23(7):839-849. doi: 10.1038/nm.4357. Epub 2017 Jun 12.

PMID:
28604703
17.

Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo.

Allweiss L, Volz T, Giersch K, Kah J, Raffa G, Petersen J, Lohse AW, Beninati C, Pollicino T, Urban S, Lütgehetmann M, Dandri M.

Gut. 2018 Mar;67(3):542-552. doi: 10.1136/gutjnl-2016-312162. Epub 2017 Apr 20.

PMID:
28428345
18.

Haem oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice.

Kah J, Volz T, Lütgehetmann M, Groth A, Lohse AW, Tiegs G, Sass G, Dandri M.

Liver Int. 2017 Aug;37(8):1128-1137. doi: 10.1111/liv.13347. Epub 2017 Jan 25.

PMID:
27992676
19.
20.

Serum HBV pgRNA as a clinical marker for cccDNA activity.

Giersch K, Allweiss L, Volz T, Dandri M, Lütgehetmann M.

J Hepatol. 2017 Feb;66(2):460-462. doi: 10.1016/j.jhep.2016.09.028. Epub 2016 Nov 5. No abstract available.

PMID:
27826059
21.

A Slow Maturation Process Renders Hepatitis B Virus Infectious.

Seitz S, Iancu C, Volz T, Mier W, Dandri M, Urban S, Bartenschlager R.

Cell Host Microbe. 2016 Jul 13;20(1):25-35. doi: 10.1016/j.chom.2016.05.013. Epub 2016 Jun 16.

22.

Mechanism of Hepatitis B Virus Persistence in Hepatocytes and Its Carcinogenic Potential.

Dandri M, Petersen J.

Clin Infect Dis. 2016 Jun 1;62 Suppl 4:S281-8. doi: 10.1093/cid/ciw023. Review.

23.

Experimental in vitro and in vivo models for the study of human hepatitis B virus infection.

Allweiss L, Dandri M.

J Hepatol. 2016 Apr;64(1 Suppl):S17-S31. doi: 10.1016/j.jhep.2016.02.012. Review.

PMID:
27084033
24.

Primary Human Hepatocytes Repopulate Livers of Mice After In Vitro Culturing and Lentiviral-Mediated Gene Transfer.

Bierwolf J, Volz T, Lütgehetmann M, Allweiss L, Riecken K, Warlich M, Fehse B, Kalff JC, Dandri M, Pollok JM.

Tissue Eng Part A. 2016 May;22(9-10):742-53. doi: 10.1089/ten.TEA.2015.0427.

25.

Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation.

Allweiss L, Gass S, Giersch K, Groth A, Kah J, Volz T, Rapp G, Schöbel A, Lohse AW, Polywka S, Pischke S, Herker E, Dandri M, Lütgehetmann M.

J Hepatol. 2016 May;64(5):1033-1040. doi: 10.1016/j.jhep.2016.01.011. Epub 2016 Jan 22.

PMID:
26805671
26.

Variability in long-term hepatitis B virus dynamics under antiviral therapy.

Murray JM, Stancevic O, Lütgehetmann M, Wursthorn K, Petersen J, Dandri M.

J Theor Biol. 2016 Feb 21;391:74-80. doi: 10.1016/j.jtbi.2015.12.005. Epub 2015 Dec 23.

PMID:
26723531
27.

The challenge of protecting without overprotecting: The two sides of myeloid-derived suppressor cells in hepatitis B viral infection.

Dandri M, Bockmann JH.

Hepatology. 2016 Mar;63(3):1043-6. doi: 10.1002/hep.28385. Epub 2016 Jan 14. No abstract available.

PMID:
26661682
28.

Hepatitis B and Delta Virus: Advances on Studies about Interactions between the Two Viruses and the Infected Hepatocyte.

Giersch K, Dandri M.

J Clin Transl Hepatol. 2015 Sep 28;3(3):220-9. doi: 10.14218/JCTH.2015.00018. Epub 2015 Sep 15. Review.

29.

Latest developments in the treatment of hepatitis B.

Dandri M, Petersen J.

Minerva Gastroenterol Dietol. 2016 Mar;62(1):88-102. Epub 2015 Oct 8. Review.

PMID:
26448309
30.

Comparison of autochthonous and imported cases of hepatitis A or hepatitis E.

Hartl J, Kreuels B, Polywka S, Addo M, Luethgehetmann M, Dandri M, Dammermann W, Sterneck M, Lohse AW, Pischke S.

Z Gastroenterol. 2015 Jul;53(7):639-43. doi: 10.1055/s-0034-1399236. Epub 2015 Jul 13.

PMID:
26167693
31.

Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibody.

Mailly L, Xiao F, Lupberger J, Wilson GK, Aubert P, Duong FHT, Calabrese D, Leboeuf C, Fofana I, Thumann C, Bandiera S, Lütgehetmann M, Volz T, Davis C, Harris HJ, Mee CJ, Girardi E, Chane-Woon-Ming B, Ericsson M, Fletcher N, Bartenschlager R, Pessaux P, Vercauteren K, Meuleman P, Villa P, Kaderali L, Pfeffer S, Heim MH, Neunlist M, Zeisel MB, Dandri M, McKeating JA, Robinet E, Baumert TF.

Nat Biotechnol. 2015 May;33(5):549-554. doi: 10.1038/nbt.3179. Epub 2015 Mar 23.

32.

Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection.

Giersch K, Allweiss L, Volz T, Helbig M, Bierwolf J, Lohse AW, Pollok JM, Petersen J, Dandri M, Lütgehetmann M.

J Hepatol. 2015 Aug;63(2):346-53. doi: 10.1016/j.jhep.2015.03.011. Epub 2015 Mar 17.

PMID:
25795587
33.

Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure.

Bockmann JH, Dandri M, Lüth S, Pannicke N, Lohse AW.

World J Gastroenterol. 2015 Feb 21;21(7):2214-9. doi: 10.3748/wjg.v21.i7.2214.

34.

Optimal therapy for chronic hepatitis B: hepatitis B virus combination therapy?

Petersen J, Dandri M.

Liver Int. 2015 Jan;35 Suppl 1:114-20. doi: 10.1111/liv.12720. Review.

PMID:
25529096
35.

Relevance of a full-length genomic RNA standard and a thermal-shock step for optimal hepatitis delta virus quantification.

Homs M, Giersch K, Blasi M, Lütgehetmann M, Buti M, Esteban R, Dandri M, Rodriguez-Frias F.

J Clin Microbiol. 2014 Sep;52(9):3334-8. doi: 10.1128/JCM.00940-14. Epub 2014 Jul 2.

36.

Matrix conditions and KLF2-dependent induction of heme oxygenase-1 modulate inhibition of HCV replication by fluvastatin.

Wuestenberg A, Kah J, Singethan K, Sirma H, Keller AD, Rosal SR, Schrader J, Loscher C, Volz T, Bartenschlager R, Lohmann V, Protzer U, Dandri M, Lohse AW, Tiegs G, Sass G.

PLoS One. 2014 May 6;9(5):e96533. doi: 10.1371/journal.pone.0096533. eCollection 2014.

37.

Binding of hepatitis B virus to its cellular receptor alters the expression profile of genes of bile acid metabolism.

Oehler N, Volz T, Bhadra OD, Kah J, Allweiss L, Giersch K, Bierwolf J, Riecken K, Pollok JM, Lohse AW, Fehse B, Petersen J, Urban S, Lütgehetmann M, Heeren J, Dandri M.

Hepatology. 2014 Nov;60(5):1483-93. doi: 10.1002/hep.27159. Epub 2014 May 19.

PMID:
24711282
38.

Mouse models of hepatitis B and delta virus infection.

Dandri M, Lütgehetmann M.

J Immunol Methods. 2014 Aug;410:39-49. doi: 10.1016/j.jim.2014.03.002. Epub 2014 Mar 12.

PMID:
24631647
39.

Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA.

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U.

Science. 2014 Mar 14;343(6176):1221-8. doi: 10.1126/science.1243462. Epub 2014 Feb 20.

40.

Multiplexing clonality: combining RGB marking and genetic barcoding.

Cornils K, Thielecke L, Hüser S, Forgber M, Thomaschewski M, Kleist N, Hussein K, Riecken K, Volz T, Gerdes S, Glauche I, Dahl A, Dandri M, Roeder I, Fehse B.

Nucleic Acids Res. 2014 Apr;42(7):e56. doi: 10.1093/nar/gku081. Epub 2014 Jan 29.

41.

Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration.

Allweiss L, Volz T, Lütgehetmann M, Giersch K, Bornscheuer T, Lohse AW, Petersen J, Ma H, Klumpp K, Fletcher SP, Dandri M.

J Hepatol. 2014 Mar;60(3):500-7. doi: 10.1016/j.jhep.2013.10.021. Epub 2013 Oct 26.

PMID:
24398036
42.

Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection.

Giersch K, Helbig M, Volz T, Allweiss L, Mancke LV, Lohse AW, Polywka S, Pollok JM, Petersen J, Taylor J, Dandri M, Lütgehetmann M.

J Hepatol. 2014 Mar;60(3):538-44. doi: 10.1016/j.jhep.2013.11.010. Epub 2013 Nov 23.

PMID:
24280293
43.

The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.

Volz T, Allweiss L, Ben MBarek M, Warlich M, Lohse AW, Pollok JM, Alexandrov A, Urban S, Petersen J, Lütgehetmann M, Dandri M.

J Hepatol. 2013 May;58(5):861-7. doi: 10.1016/j.jhep.2012.12.008. Epub 2012 Dec 13.

PMID:
23246506
44.

Dissecting the divergent effects of interferon-alpha on immune cells: time to rethink combination therapy in chronic hepatitis B?

Thimme R, Dandri M.

J Hepatol. 2013 Feb;58(2):205-9. doi: 10.1016/j.jhep.2012.11.007. Epub 2012 Nov 14. No abstract available.

45.

Experimental models and therapeutic approaches for HBV.

Dandri M, Lütgehetmann M, Petersen J.

Semin Immunopathol. 2013 Jan;35(1):7-21. doi: 10.1007/s00281-012-0335-7. Epub 2012 Aug 17. Review.

PMID:
22898798
46.

Selective induction of apoptosis by HMG-CoA reductase inhibitors in hepatoma cells and dependence on p53 expression.

Kah J, Wüstenberg A, Keller AD, Sirma H, Montalbano R, Ocker M, Volz T, Dandri M, Tiegs G, Sass G.

Oncol Rep. 2012 Sep;28(3):1077-83. doi: 10.3892/or.2012.1860. Epub 2012 Jun 12.

PMID:
22710979
47.

Primary human hepatocytes from metabolic-disordered children recreate highly differentiated liver-tissue-like spheroids on alginate scaffolds.

Bierwolf J, Lutgehetmann M, Deichmann S, Erbes J, Volz T, Dandri M, Cohen S, Nashan B, Pollok JM.

Tissue Eng Part A. 2012 Jul;18(13-14):1443-53. doi: 10.1089/ten.TEA.2012.0029. Epub 2012 Jun 27.

PMID:
22612238
48.

New insight in the pathobiology of hepatitis B virus infection.

Dandri M, Locarnini S.

Gut. 2012 May;61 Suppl 1:i6-17. doi: 10.1136/gutjnl-2012-302056. Review.

PMID:
22504921
49.

Strong antiviral activity of the new l-hydroxycytidine derivative, l-Hyd4FC, in HBV-infected human chimeric uPA/SCID mice.

Volz T, Lütgehetmann M, Allweiss L, Warlich M, Bierwolf J, Pollok JM, Petersen J, Matthes E, Dandri M.

Antivir Ther. 2012;17(4):623-31. doi: 10.3851/IMP2075. Epub 2012 Feb 27.

PMID:
22368233
50.

IFN-α inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome.

Belloni L, Allweiss L, Guerrieri F, Pediconi N, Volz T, Pollicino T, Petersen J, Raimondo G, Dandri M, Levrero M.

J Clin Invest. 2012 Feb;122(2):529-37. doi: 10.1172/JCI58847. Epub 2012 Jan 17.

Supplemental Content

Loading ...
Support Center